Medidata and Medpace Sign Agreement to Integrate Imaging and Clinical Data into a Single Platform
NEW YORK--(BUSINESS WIRE)--Mar 4, 2020--
Medidata, the global leader in creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that Medpace Inc. has entered into an agreement to integrate Medidata Rave Imaging with Medpace’s imaging systems and workflow. This will create a seamless platform for capturing, managing, analyzing and storing images and imaging data for clinical trials. Medpace is a leading contract research organization (CRO) with a wholly-owned and fully integrated imaging core lab that offers a suite of global imaging services to enhance and expedite biopharmaceutical and medical device development.
“Medidata is transforming the way the healthcare industry incorporates and leverages imaging in clinical trials,” said Glen de Vries, co-founder and co-CEO, Medidata. “As drug and medical device development depend more on medical imaging, it’s more important than ever to simplify and unify image and data collection. This helps to minimize risk and complexity, and ensures accurate, rapid completion of clinical studies so patients can more quickly benefit from new therapeutics.”
The use and importance of medical imaging in clinical studies continues to grow. Today, over 50 percent of all studies use medical imaging to help determine the efficacy of new drugs and devices and 95 percent when it is an oncology study. Medidata Rave Imaging is an end-to-end cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, electronic data capture (EDC) connection, and intelligent archiving. Medidata processes more than 500 million images annually from nearly 800 studies.
Using Medidata Rave Imaging, Medpace’s imaging core lab will:
- Provide Medpace customers with a single, familiar location for site data entry and image uploads
- Optimize resources and workflow, reduce manual reconciliation steps, increase data visibility, and create a single data repository on a unified trial platform
- Compute quantitative imaging biomarkers for clinical trials in oncology, metabolic disease, and neuroscience
- Create an integrated workflow to determine patient eligibility, monitor disease progression or response, and make go / no go clinical decisions that provide customers with a more streamlined and effective approach for managing vital imaging components of their study
“Through our partnership with Medidata, Medpace is now able to provide seamless integration of our quantitative image analysis pipelines with Medidata’s Rave Imaging system and database,” said Daniel O’Leary, MD, chief medical officer for Medpace’s imaging core lab. “The combination of these tools produces the most powerful imaging trial management environment currently available to the clinical trial market.”
Medidata is part of Dassault Systèmes, which is positioned to lead the digital transformation of life sciences in the age of personalized medicine with an end-to-end offering from research to commercialization.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life Sciences™.
Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,500 people across 37 countries.
Medpace’s imaging core lab offers a full range of medical imaging capabilities for clinical trials across therapeutic areas; functioning either as a stand-alone core lab, in partnership with other CROs, or seamlessly integrated with Medpace’s scientifically-driven clinical teams. Medpace supports all imaging modalities and offers Independent Image Reviewer services for clinical trials from a panel of board-certified physicians and radiologists. Medpace core lab staff includes physicians and scientists with medical imaging expertise, board certified imaging technologists and project management teams based in the US, Europe and Asia. More information about our processes and experience can be found on our website at: https://www.medpace.com/labs/core-labs/
View source version on businesswire.com:https://www.businesswire.com/news/home/20200304005523/en/
CONTACT: Rosemarie Esposito
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: DATA MANAGEMENT BIOTECHNOLOGY TECHNOLOGY HEALTH RADIOLOGY PHARMACEUTICAL ONCOLOGY MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS
Copyright Business Wire 2020.
PUB: 03/04/2020 10:30 AM/DISC: 03/04/2020 10:30 AM